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Amyloid β (Aβ) is themajor constituent of the brain deposits found in parenchymal plaques
and cerebral blood vessels of patients with Alzheimer’s disease (AD). Several lines of
investigation support the notion that synaptic pathology, one of the strongest correlates
to cognitive impairment, is related to the progressive accumulation of neurotoxic Aβ
oligomers. Since the process of oligomerization/fibrillization is concentration-dependent,
it is highly reliant on the homeostatic mechanisms that regulate the steady state
levels of Aβ influencing the delicate balance between rate of synthesis, dynamics of
aggregation, and clearance kinetics. Emerging new data suggest that reduced Aβ
clearance, particularly in the aging brain, plays a critical role in the process of amyloid
formation and AD pathogenesis. Using well-defined monomeric and low molecular mass
oligomeric Aβ1-40 species stereotaxically injected into the brain of C57BL/6 wild-type
mice in combination with biochemical and mass spectrometric analyses in CSF, our
data clearly demonstrate that Aβ physiologic removal is extremely fast and involves
local proteolytic degradation leading to the generation of heterogeneous C-terminally
cleaved proteolytic products, while providing clear indication of the detrimental role of
oligomerization for brain Aβ efflux. Immunofluorescence confocal microscopy studies
provide insight into the cellular pathways involved in the brain removal and cellular
uptake of Aβ. The findings indicate that clearance from brain interstitial fluid follows
local and systemic paths and that in addition to the blood-brain barrier, local enzymatic
degradation and the bulk flow transport through the choroid plexus into the CSF play
significant roles. Our studies highlight the diverse factors influencing brain clearance and
the participation of various routes of elimination opening up new research opportunities
for the understanding of alteredmechanisms triggering AD pathology and for the potential
design of combined therapeutic strategies.
Keywords: Aβ brain efflux, Aβ brain homeostasis, local proteolytic degradation, stereotaxic intra-cerebral injection,
targeted mass spectrometric analysis, cerebrospinal fluid
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INTRODUCTION
The most frequent form of amyloidosis in humans is related to
the deposition of amyloid-β (Aβ) in Alzheimer’s disease (AD),
with cumulative biochemical, genetic, and in vivo data strongly
suggesting a central role for this molecule in the pathogenesis of
the disorder. Aβ is the major constituent of the tissue deposits
found in parenchymal plaques and cerebral blood vessels of
patients with AD andwithDown’s syndrome, the latter exhibiting
a trisomy in chromosome 21 which codes for the Amyloid
Precursor Protein (APP) and lead to AD pathology by middle
age (Masters et al., 1985a; Busciglio et al., 2002). Indeed, Aβ
is an internal processing product of this transmembrane APP
precursor molecule (Querfurth and LaFerla, 2010; Rostagno
et al., 2010) generated through proteolytic cleavage by the β-
and γ-secretases (Masters et al., 1985b; Kang et al., 1987; Ghiso
and Frangione, 2002). Although it is unclear what primarily
triggers and drives the progression of AD, histopathologic,
genetic, biochemical, and physicochemical studies, together with
information obtained from transgenic animal models, strongly
support the notion that abnormal aggregation/fibrillization, and
subsequent Aβ tissue accumulation are key players in the
disease pathogenesis (Mattson, 2004; Walsh and Selkoe, 2007;
Querfurth and LaFerla, 2010; Holtzman et al., 2011). Although
the abundance of mature amyloid plaques correlates poorly with
AD severity (Lue et al., 1999; McLean et al., 1999), current
data indicate that the transition from soluble monomeric species
normally found in circulation to oligomeric, protofibrillar, and
end-point fibrillar assemblies contribute significantly to disease
pathogenesis. Intermediate oligomeric and protofibrillar forms,
in particular, seem to display the most potent effects in neuronal
cells, inducing synaptic disruption and neurotoxicity (Caughey
and Lansbury, 2003; Walsh and Selkoe, 2007). Numerous studies
have shown that these soluble oligomeric forms of Aβ—which
have been identified in vivo and isolated from brain, plasma, and
CSF (Kuo et al., 1996; Roher et al., 1996, 2000)—are capable
of affecting synaptic function by various mechanisms (Galvan
and Hart, 2016), impairing glutamatergic synaptic transmission
strength and plasticity, altering synaptic structure (Whalen et al.,
2005), reducing efficacy of synapses and causing synaptic loss
(Walsh et al., 2002; Haass and Selkoe, 2007; Nicholls et al., 2008).
The process of oligomerization/fibrillization is concentration-
dependent, and therefore it is highly reliant on the homeostatic
mechanisms that regulate the steady state levels of Aβmodulating
the delicate balance between rate of synthesis, dynamics of
aggregation, and rate of brain eﬄux. For the majority of AD
cases, which are of late-onset and of sporadic origin, the
cause of this imbalance is unclear and remains a subject of
active investigation. While to date no evidence supports an
increase in the overall production in sporadic cases, current
research suggests that an impaired clearance in late onset AD
plays a critical role in the process of amyloid formation and
the pathogenesis of the disease (Mawuenyega et al., 2010).
Many pathways are currently being investigated, among them
perivascular drainage, receptor-mediated cell uptake, blood
brain barrier (BBB) transport, and local proteolytic degradation,
all undoubtedly contributors to brain Aβ clearance (Deane
et al., 2004, 2009; Bakker et al., 2016; Morris et al., 2016) in
conjunction with the bulk flow of ISF into the CSF through the
choroid plexus epithelium, which remarkably shares many of
the receptors involved in BBB clearance (Dietrich et al., 2008;
Behl et al., 2009) as well as the recently described paths for
CSF recycling through the ISF (Iliff et al., 2012). Notably, in
spite of the relevance of Aβ oligomerization for the disease
pathogenesis, the vast majority of the reported Aβ clearance
data have been generated with monomeric Aβ species or with
peptides with poorly characterized aggregation state (Zlokovic
et al., 1993; Ghersi-Egea et al., 1996; Martel et al., 1997; Mackic
et al., 1998; Poduslo et al., 1999; Shibata et al., 2000; Strazielle
et al., 2000; Bading et al., 2002; Devi and Ohno, 2012). The
present work was designed to address this gap in knowledge
and provide quantitative evaluation of the differential brain
removal efficiency of pathogenic oligomeric Aβ assemblies
while providing information into the relevance of the in situ
catabolic break-down of the peptide. Based on data from
intra-cerebral stereotaxic injections of well-defined monomeric
and low molecular mass oligomeric Aβ assemblies in C57BL/6
wild-type mice in combination with biochemical and mass
spectrometry analyses in CSF, the current work highlights
the fast physiologic degradation and brain elimination of the
peptide and provides a clear indication of the detrimental role
of oligomerization for brain Aβ eﬄux. Immunofluorescence
confocal microscopy studies bring insight into the cellular
pathways involved in the brain clearance and cellular
uptake of Aβ.
MATERIALS AND METHODS
Peptide Synthesis, Solubilization, and
Oligomerization
Aβ1–40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIG
LMVGGVV) homologous to residues 672–711 of human Aβ
precursor protein APP770 was synthesized by J. Elliot at the W.
M. Keck Facility at Yale University usingN-tert-butyloxycarbonyl
chemistry and purified by reverse phase-high performance liquid
chromatography on a Vydac C4 column (Western Analytical,
Murrieta, CA). The molecular mass of the synthetic homolog was
corroborated bymatrix-assisted laser desorption ionization time-
of-flight (MALDI-ToF) mass spectrometry, and its concentration
assessed by amino acid analysis, as we previously reported (Ghiso
et al., 2004). The peptide eluted as a single component from the
HPLC column and exhibited an experimental molecular mass of
4329.1 Da (theoretical mass: 4329.9 Da).
Aβ1-40 was incubated at a concentration of 1mg/ml in
1,1,1,3,3,3, hexafluoro-isopropanol (HFIP; Sigma Chemical Co.,
St. Louis, MO) for 24 h, a pretreatment that breaks down β -
sheet structures and disrupts hydrophobic forces leading to
monodisperse amyloid subunit preparations (Stine et al., 2003).
The HFIP-pretreated peptide was lyophilized, subsequently
reconstituted to 1mM in deionized water followed by further
dilution in 2X phosphate-buffered saline (PBS) to a final
concentration of 1µg/µl in PBS and either immediately
used for radioiodination and direct intracerebral injection or
maintained frozen at −80◦C, storage conditions that preserved
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the monomeric structures, for up to 1 month. For the studies
involving clearance of Aβ oligomers, Aβ1-40—reconstituted in
PBS as above—was aggregated for 24 h at 37◦C to generate low
molecular mass oligomers, as we previously described (Fossati
et al., 2010), prior to radioiodination, since labeling stably formed
Aβ assemblies is known to render labeled preparations with
unperturbed structural morphology preventing the generation
of undesired atypical oligomers (Jungbauera et al., 2009).
The resulting Aβ1-40 oligomers were immediately used for
radiolabeling, for direct intracerebral injections (see below)
or stored at −80◦C, condition that preserved the original
oligomerization structures for up to 2 weeks.
Peptide oligomerization was corroborated via electron
microscopy (EM), as previously described (Fossati et al., 2010).
Five microliters of either monomeric or oligomeric Aβ1-40
preparations were placed onto carbon-coated 400 mesh Cu/Rh
grids (Ted Pella, Inc., Redding, CA) and stained with 1% uranyl
acetate in distilled water (Polysciences, Inc., Warrington, PA).
Stained grids were examined in a Philips CM-12 transmission
electron microscope and photographed with a Gatan (4 × 2.7 k)
digital camera at the Image Core Facility of the Skirball Institute
of Biomedical Medicine, NYU School of Medicine, as described
(Solito et al., 2009; Fossati et al., 2010).
Peptide Radiolabeling
Aβ1-40 in both monomeric and oligomeric forms was
radiolabeled using 1,3,4,6-tetrachloro-3α-6α-diphenylglycouril
pre-coated tubes (Iodogen, ThermoFisher Scientific/Pierce,
Waltham, MA), following the manufacturer’s specifications.
All radiolabeling procedures were carried out in a Standalone
Radioiodine IH-350 hood (Atlantic Nuclear, Rockland, MA).
Na125I in NaOH (1mCi, PerkinElmer, Waltham, MA) was added
to an Iodotube and combined with 20µl of 0.1M HCl and 60
µl of 1/10 diluted PBS. After 5-min incubation, the reaction
tube was added of either monomeric or oligomeric Aβ1-40
(1µg/µl; 100µl), prepared as above, and the radiolabeling
reaction carried out for 20 min. Following removal of free
Iodine using a desalting polyacrylamide column (D-salt, cut off
1.8 kDa, Pierce), radioactivity of labeled Aβ1-40 was assessed
in a scintillation counter (LS 6500 Multi-purpose Scintillation
Counter, Beckman Coulter, Brea, CA). [125I]Aβ1-40 was analyzed
by autoradiography following 16.5% SDS-polyacrylamide gel
electrophoresis and subsequent direct exposure to HyBlot CL
film (Denville Scientific Inc., South Plainfield, NJ). Iodinated
Aβ peptides were stored at –80
◦
C and used within 2 weeks to
minimize radiolysis. Under these experimental conditions, [125I]
incorporation rendered specific activities in the range of 3–5
µCi/µg with >98% TCA precipitable counts (Ghiso et al., 2004;
Calero and Ghiso, 2005).
Intracerebral Inoculation of
Radio-Iodinated Aβ1-40
C57BL/6 mice (Taconic Biosciences, Hudson, NY), were
intracerebrally injected with Aβ1-40 preparations following
institutionally approved IACUC protocols, essentially as
previously reported by our laboratory (Fossati et al., 2016).
Briefly, 26–30 week oldmice were anesthetized by i.p. injection of
a mixture of ketamine/xylazine (120 and 10 mg/kg respectively),
positioned in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA), and intracerebrally injected (white matter of the
fimbria fornix; Paxinos and Franklin Atlas coordinates: AP =
−2.7, ML=−3.0 and DV=−4.0) with 1µl of either monomeric
or oligomeric [125I]Aβ1-40 (10 µM; flow rate: 0.2µl/min) with
the aid of a 10µl Hamilton 701 RN syringe and a 30/2′′/3S
RN needle. To avoid reflux, the needle was left in position for
2min after injection and then slowly withdrawn. At the selected
time points after injection (5, 30, and 60min), the animals were
subjected to CSF collection as described below, sacrificed by
trans-cardiac perfusion with PBS (2min, medium flow pump,
Fisher Scientific 13-876-2, 10ml/min flow rate) followed by
tissue harvest. Radioactivity remaining in the whole brain and
cleared to CSF was assessed in an automated γ-counter (Perkin
Elmer 1470).
Intracerebral Inoculation of
Non-Radiolabeled Aβ1-40 and Collection of
Cerebral Spinal Fluid
For the proteomic experiments described below, C57BL/6 mice
were anesthetized and injected intracerebrally with non-labeled
monomeric and oligomeric Aβ1-40 using the same methodology
as described above for the inoculation of the radioiodinated
peptides. At selected time points after inoculation (5, 30, and
60min) CSF was collected from the cisterna magna following
previously reported procedures (Liu and Duff, 2008) and in
accordance with IACUC institutionally approved protocols.
Briefly, after performing a 2 cm incision at the base of the
skull, subcutaneous skin and neck muscles were separated with
the aid of small animal micro-retractors (Fine Science Tools,
Foster City, CA) to expose the dura mater of the cisterna
magna. A siliconized borosilicate glass capillary (B100-75-10,
Sutter Instruments, Novato, CA) was inserted through the dura
mater, CSF was drawn into the capillary, and collected completely
clear of blood. CSF samples, typically 5–8µl per animal, were
immediately frozen and stored at −80◦ C for future proteomic
analysis.
Immunohistochemical Analysis of Brain
Tissue Post-Aβ Injection
Following intracerebral injection of non-iodinated
monomeric/oligomeric Aβ and CSF collection, mice were
sacrificed as above by trans-cardiac perfusion with PBS
(2min) followed by 4% paraformaldehyde (5min). Brains
were harvested, post-fixed in 4% paraformaldehyde (2 h,
4◦C), and cryoprotected by immersion in increasing sucrose
concentrations (1 day in 15% followed by 2 days in 30%
solution) before freezing as previously described (Fossati
et al., 2016). Serial 8 µm-cryostat sections were collected on
positively charged microscope slides and stored at −80◦C until
analysis. Prior to staining, sections were briefly warmed to
room temperature, washed with PBS, blocked in 5% milk in
PBS (1 h), and incubated in the different primary antibodies
shown in Table 1 (overnight, 4◦C). Slides were subsequently
washed with PBS, and further incubated with the pertinent
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TABLE 1 | Primary antibodies for immunohistochemical studies.
Name Species Source Dilution
Aβ, 6E10 Mouse monoclonal Covance (SIG-39320) 1:200
CD-163 Goat polyclonal Santa Cruz (SC-18796) 1:100
E-Cadherin Rabbit polyclonal Abcam (15148) 1:200
Factor-VIII Rabbit polyclonal Abcam (6994–100) 1:200
GFAP Rabbit polyclonal Life Technologies (Z0334) 1:200
Iba-1 Goat polyclonal Abcam (5076–100) 1:100
Neurotubulin Rabbit polyclonal Abcam (18207) 1:100
anti-rabbit, anti-mouse, or anti-goat secondary antibodies
conjugated to Alexafluor 568 (red signal) or Alexafluor 488
(green fluorescence; ThermoFisher/Life Technologies, Waltham,
MA; 1:200, 30min, RT). DNA was counterstained with TO-PRO
(ThermoFisher/Life Technologies; 1:2000, 10 min), and sections
were mounted with aqueous mounting medium (Vectashield,
Vector, Olean, NY). Images were acquired in a Zeiss LSM510
confocal microscope with a 40X/1.3 oil immersion lens and
processed with Image J (https://imagej.nih.gov) and Adobe
Photoshop (Adobe, San Jose, CA).
Assessment of Differential Brain Aβ Local
Degradation by Immunoprecipitation and
Mass Spectrometry
Upon intracerebral injection of non-radiolabeled
monomeric/oligomeric Aβ1-40 and collection of CSF as
described above, Aβ species in the biological fluid were
immunoprecipitated with paramagnetic beads (Dynabeads M-
280, Life Technologies) coated with 6E10 antibody (6µg/50µl
beads), and analyzed by MALDI-ToF MS, following previously
described methodologies by our laboratory (Tomidokoro
et al., 2005, 2010; Hernandez-Guillamon et al., 2015). Each
immunoprecipitated sample consisted of a pool of four
individual CSF specimens collected from individual mice
injected with non-labeled Aβ under identical conditions (n = 8).
Samples were immunoprecipitated overnight at 4◦C, beads
washed with PBS containing 0.025% Tween-20 followed by
50mM NH4HCO3, and the immunoprecipitated material
subsequently eluted with 0.5 M acetic acid. After drying in
a Savant SpeedVac concentrator (ThermoFisher), samples
were reconstituted in 5 µl of 0.1% Formic Acid (FA) in 50%
acetonitrile, and mixed with equal volumes of alpha-4-hydroxy-
cinnamic-acid (AHCA; Agilent Technologies) matrix. One
microliter of the final mixture was spotted in duplicate on a
Bruker Daltonics MTP 384 massive target T aluminum plate and
analyzed at the New York University Mass Spectrometry Core
for Neuroscience using a Bruker Daltonics Autoflex MALDI-
ToF mass spectrometer (Bremen, Germany) in linear mode
with standard instrument settings, as described (Hernandez-
Guillamon et al., 2015). External calibration was performed using
human adrenocorticotropic hormone peptide 18-39 (average
mass= 2465.68 Da) and insulin (average mass= 5733.49 Da). In
all cases MS spectra were processed and analyzed by FlexAnalysis
(Bruker Daltonics).
Statistical Analysis
ANOVA for comparison of multiple groups with Tukey post-hoc
tests were performed using GraphPad Prism (GraphPad, La Jolla,
CA). Values of p ≤ 0.05 were considered significant.
RESULTS
Monomeric and oligomeric of Aβ1-40 preparations were labeled
with Na[125I] at the tyrosine residue located at position
10 of Aβ (Figure 1A), as described above in Material and
Methods. The use of a 1.8 kDa cut off desalting column
allowed the removal of free iodine from radio-iodinated Aβ,
as illustrated in Figure 1B by the clear separation between
peaks in a representative experiment. Autoradiography after
SDS-gel electrophoresis confirmed the respective monomeric
or oligomeric composition of each respective preparation. As
indicated in the pertinent autoradiograms shown in Figure 1C,
monomeric preparations displayed a single 4 kDa band
whereas oligomeric preparations consisted of low molecular
mass Aβ species, exhibiting monomeric, dimeric, trimeric, and
tetrameric components with predominance of dimeric forms.
The monomeric or oligomeric nature of the preparations
was corroborated via EM in parallel experiments performed
using non-labeled counterparts. As illustrated in Figure 1C,
monomeric preparations rendered scattered globular structures
4–6 nm in diameter whereas oligomeric preparations contained
a higher number of the same globular structures in many cases
associated in small groups containing 2–4 globular components.
No evidence of protofibrillar formation was noticed at this
time-point, in agreement with our previous reports (Solito
et al., 2009; Viana et al., 2009; Fossati et al., 2010). Classic
protofibrils (short rods of <150 nm in length and 4–6 nm in
diameter) did not appear before an additional 24 h incubation
in our experimental conditions, providing the necessary safety
net of structural stability for the 1 h window of our intra-
cerebral injection experiments. Both monomeric and oligomeric
preparations were intra-cerebrally inoculated into C57BL/6 mice
to evaluate their respective eﬄux from brain. The schematic
representation in Figure 1D depicts the injection coordinates
and the needle position whereas immunostaining at the actual
injection site using anti-Aβ monoclonal 6E10 and Alexafluor
488 conjugates demonstrates minimal—although unavoidable—
tissue disruption (right panel). Specificity of the immunostaining
is indicated by the absence of Aβ signal in the contralateral site in
animals sacrificed immediately after inoculation (left panel).
Figure 2A depicts the time-related clearance of monomeric
and LMW oligomeric [125I]Aβ1-40 from brain interstitial fluid,
estimated based on the radioactivity remaining in the whole
brain at 5, 30, and 60 min post-injection compared to the
total injected radioactivity. Brain eﬄux of monomeric Aβ1-
40 was fast, with ∼25% of the peptide cleared in only
5min and >60% cleared within 60min. Retention of LMW
oligomers was consistently higher, with only ∼15% of the
injected material eliminated in the first 5min and <40% at
60min. Comparison of brain clearance levels for monomeric
vs. oligomeric forms of [125I]Aβ1-40 evaluated 60min after
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FIGURE 1 | Aβ1-40 radioiodination, assessment of peptide oligomerization and intra-cerebral injection. (A) Amino acid sequence of Aβ1-40 highlighting the
location of tyrosine 10, the target of the radioiodination procedure (red arrow). (B) Representative separation of [125 I]-labeled Aβ1-40 from free iodine using a desalting
1.8 kDa cut-off polyacrylamide column. (C) Autoradiogram following electrophoretic separation of monomeric and oligomeric preparations of radiolabeled Aβ1-40 on
16.5% SDS-polyacrylamide gels (top) and EM images illustrating the differential conformational assemblies negatively stained with uranyl acetate (bottom).
Magnification: bar represents 100 nm. (D) Schematic representation of the needle location for the intra-cerebral injection of Aβ1-40 preparations (top panel) and
immunostaining with monoclonal anti-Aβ 6E10 followed by Alexafluor 488 conjugated secondary antibody and DAPI counterstain at the injection site demonstrating
minimal—although unavoidable—tissue disruption (bottom right panel). The absence of Aβ signal in the contralateral site in animals sacrificed immediately after Aβ
injection corroborates the specificity of the immunostaining (bottom left panel). Magnification: bar represents 100µm.
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FIGURE 2 | Brain clearance of radiolabeled Aβ species. (A) Clearance of monomeric (black bars) and oligomeric (gray bars) [125 I]Aβ1-40 species removed from
the brain at three different time-points. (B) Monomeric (black bars) and oligomeric (gray bars) [125 I]Aβ1-40 species cleared to the CSF evaluated at three different
time-points. In all cases bars illustrate percentage cleared relative to total injected radioactivity; values represent mean ± SD obtained from inoculation of 5–7 mice
(ANOVA and Tukey post-hoc test; ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001).
intra-cerebral injection clearly demonstrated that peptide
oligomerization significantly increased brain retention (p <
0.001). Clearance from interstitial fluid to the CSF was evaluated
by quantitating radioactivity in the CSF 5, 30, and 60min
post-Aβ intracerebral injection (Figure 2B). CSF was collected
through a cisterna magna puncturing technique without blood
contamination, as corroborated by dot blot analysis probed
with antibodies immunoreacting with apolipoprotein-B and α2-
macrogloblin, blood proteins not present in the CSF (data not
shown). Only a fraction of the material removed from brain
reached the CSF in a time-dependent manner. In the case of
monomeric Aβ1-40, the levels cleared to the CSF increased from
∼3% at 5 min to an average of 13% at 60min. In contrast, LMW
oligomeric Aβ1-40 was cleared less efficiently, with only ∼2%
present in the CSF after 5min, and ∼4% at 60min. Comparative
evaluation of [125I]-Aβ cleared to the CSF at 60min indicates
a statistically significant decrease of about 3-fold in oligomeric
Aβ removal compared to the values obtained for the monomeric
form of the peptide (p < 0.05) and in line with the results
illustrated in Figure 2A for overall brain eﬄux.
In order to biochemically analyze the Aβ species cleared
to the CSF, a targeted mass spectrometric analysis of Aβ
was conducted on CSF collected from a parallel set of
mice 5, 30, and 60min after intra-cerebral injection of non-
radiolabeled monomeric and oligomeric forms of Aβ1-40.
Immunoprecipitation of CSF samples with paramagnetic beads
coated with monoclonal anti-Aβ 6E10 antibodies followed
by MALDI-ToF mass spectrometry analysis revealed the
presence of heterogeneous C-terminally truncated Aβ species in
addition to full-length Aβ1-40, suggestive of a fast enzymatic
degradation by brain resident enzymes. Figure 3 depicts the
differential pattern exhibited by the intact injected peptide—
a single peak with an experimental mass of 4329.1Da (top
panel)—in comparison with the multiple degradation fragments
retrieved in CSF at the different time-points (lower panels).
The relative intensity ratios between the intact peptide and
each of the major proteolytically- generated fragments assessed
at the different time points indicate that the CSF truncated
Aβ species became comparatively less abundant with time
while the peak pertaining to the intact peptide, a relatively
minor component at 5min, increased as the time after
injection progressed and was the predominant form at 60min
(Figure 3). These differences in the CSF Aβ heterogeneity—
highly dependent on the time of sample collection following the
intra-cerebral Aβ injection—strongly suggest that C-terminally
degraded Aβ fragments are cleared into and out of the
CSF more efficiently than the full length peptide—likely
reflecting their higher solubility and lower tendency to aggregate
(Cabrera et al., unpublished)—and supporting the beneficial
role for local catabolism in brain Aβ eﬄux. Whether a
decreased ratio of Aβ-truncated fragments at longer time
points after injection also reflects a preferential involvement of
other Aβ-removal mechanisms including perivascular drainage,
glymphatic pathway or meningeal lymphatic vessels, and/or
simply results from the focal exhaustion of available local
enzymes remain to be elucidated.
Similar to what was observed for the injected monomeric
Aβ1-40, analysis of CSF collected from mice injected with LMW
oligomeric forms of the peptide displayed, in addition to the
full length peptide, a heterogeneous collection of C-terminally
truncated species (Figure 4). It should be noted that under
the experimental conditions of the mass spectrometry assay,
which render non-covalent binding unobservable (Woods et al.,
1995), the amyloid molecules are detected at the molecular
mass corresponding to the monomeric species, independent of
their aggregation state, as we previously reported (Tomidokoro
et al., 2010); therefore, the full-length peak is detected with the
same experimental mass regardless the use of monomers or
LMW oligomers in the experiments. Visual evaluation of the
CSF Aβ species resulting from the inoculation of monomeric vs.
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FIGURE 3 | Aβ species cleared to the CSF assessed by a combination of immunoprecipitation and mass spectrometry. MALDI-ToF spectra and
normalized ion counts of the monomeric Aβ1-40 used for the experiments prior injection (top). MS profile of the material immunoprecipitated from CSF at different time
points (5, 30, and 60min) post injection identify multiple C-terminally degraded proteolytic fragments. Immunoprecititation was performed in pooled CSF samples from
4 mice injected under the same experimental conditions in 2 independent experiments (n = 8) and spotted in duplicate in the mass spectrometer aluminum plates.
oligomeric Aβ1-40 at 30min post-injection (Figure 4, top and
bottom panels, respectively) revealed a similar heterogeneity—
full-length peptide coexisting with the same C-terminally
degraded Aβ fragments—indicative that, irrespective of the
aggregation status of the injected Aβ, the same peptide bonds
were targeted for enzymatic degradation. Analysis of the relative
intensity ratios corresponding to the intact peptide and to each of
the major proteolytic fragments generated from the monomeric
and the LMW oligomeric species reinforced the similarity of
the proteolytic process (Figure 4, normalized intensities). While
absolute signal intensity between samples in MALDI-ToF is
not reliably quantitative, lower signal intensity for the cleared
oligomeric injected forms are consistent with an indication that
Aβ1-40 full-length oligomers are not removed as efficiently to the
CSF as the monomeric form, in agreement with results illustrated
in Figure 2. The lower susceptibility of oligomeric injected forms
of Aβ to enzymatic degradation suggested by the lower signal
intensity of the C-terminally degraded derivatives—consistent
with previously reported studies for most Aβ-degrading enzymes
(Morelli et al., 2003; Haass and Selkoe, 2007; De Strooper,
2010)—may also account, at least in part, for the lower clearance
rate observed in our experimental paradigm for oligomeric Aβ
species shown in Figure 2.
Immunofluorescence confocal microscopy studies in brain
tissues harvested 60 min following intracerebral injection
of non-labeled Aβ1-40 provided insight into the cellular
mechanisms involved in Aβ uptake. Brain tissue sections were
co-immunolabeled with antibodies recognizing specific cell types
in conjunction with monoclonal anti-Aβ antibody 6E10 and co-
localization of the respective signals evaluated at the site of the
injection. The images described below were captured from the
motor cortex adjacent to the injection site. Although the distance
from the injection point varied among the different stainings,
the images shown in Figure 5 were typically acquired within
a 400µm range from the injection site. Figure 5A illustrates
the localization of injected Aβ monomers to neuronal cells
highlighted by neurotubulin staining consistent with recent
reports demonstrating the capability of neurons to uptake ISF
Aβ through receptor-mediated endocytosis by the low-density
lipoprotein receptor-related protein 1 (LRP1; Kanekiyo et al.,
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FIGURE 4 | Comparative analysis of Aβ species cleared to the CSF after intracerebral injection of monomeric and oligomeric Aβ1-40. MALDI-ToF
spectra and normalized ion counts on CSF collected 30min after intracerebral injection of comparable amounts of monomeric (top panel) and oligomeric (bottom
panel) Aβ1-40 immunoprecipitated with anti-Aβ monoclonal antibody 6E10. For the immunoprecipitation, CSF was pooled from 4 mice injected under the same
experimental conditions. Data are representative of 2 independent experiments (n = 8) spotted in duplicate in the mass spectrometer aluminum plates.
2013). Aβ was also present in the cerebral vasculature, as
indicated by its co-localization with endothelial cells decorated by
their reactivity with Factor VIII, suggestive of Aβ clearance across
the BBB, a well study pathway for the removal of Aβ monomers
(Shibata et al., 2000; Bell et al., 2007; Deane et al., 2009),
or along the peri-/para-vascular tracks, as recently reported
(Morris et al., 2016). The immunohistochemical approach also
illustrates the co-localization of Aβ with astrocytes surrounding
the vasculature—as indicated by the overlapping staining pattern
of Aβ and the astrocytic marker GFAP—indicative of the
recently described glymphatic pathway involving the aquaporin
4-mediated ISF bulk flow, as one of the mechanisms involved in
the clearance of the injected Aβ. Analysis of the choroid plexus
epithelium with antibodies recognizing E-cadherin indicates the
presence of the intra-cerebrally injected Aβ also at this barrier
structure and in accordance to the presence of degraded and
intact Aβ in the CSF illustrated in Figures 2–4. Notably, Aβ
reactivity was also associated with activated microglia within the
choroid plexus, as highlighted by the overlapping signals of Aβ
with the Iba-1 microglial marker. The immunoreactivity of 6E10
does not distinguish between monomeric and oligomeric forms
of Aβ; thus, we used this antibody in immunohistochemical
studies to also assess the localization of the injected oligomeric
preparations. As indicated above, the Aβ1–40 oligomers used
in the experiments remained stable during the 1 h window of
the intra-cerebral injection procedure requiring an additional
24 h incubation to render protofibrillar structures (Fossati
et al., 2010). Figure 5B illustrates the comparable overlapping
of signals recognizing the injected LMW oligomeric Aβ with
neuronal, endothelial, and astrocytic cells as well as within
choroid plexus structures and associated activated microglia,
suggesting the involvement of comparable routes for the eﬄux
of monomeric and LMW oligomeric Aβ counterparts.
DISCUSSION
Over the last decade increasing evidence indicates that one
of the main mechanisms leading to brain Aβ accumulation
and likely contributing to AD is a defective clearance of the
protein from the brain, which affects the delicate balance between
degree of Aβ production, dynamics of aggregation, and rate
of brain eﬄux. Glial phagocytosis, local enzymatic degradation,
eﬄux through the BBB, transport to the cerebrospinal fluid,
peri- and para-vascular drainage along with the more recently
described glymphatic system and meningeal lymphatic vessels
are among the mechanisms under current investigation and with
demonstrated participation in brain Aβ removal (Deane et al.,
2004, 2008, 2009; Iliff et al., 2012; Morris et al., 2014, 2016; Bakker
et al., 2016). Of all these pathways, clearance across the BBB
is definitely the most studied and one of the most significant
contributors to Aβ brain removal accounting for ∼75% of the
overall Aβ eﬄux in humans (Roberts et al., 2014). Once cleared
to the blood stream and consistent to its very low and steady
concentration in plasma, full-length Aβ has a very short half-
life: ∼3 min in mice, similar to that of insulin or oxytocin
(Ghiso et al., 2004). Systemic Aβ catabolism occurs mainly in
the liver through hepatocyte uptake and proteolytic degradation
followed by secretion of the intact peptide and its proteolytically-
derived fragments into the bile (Ghiso et al., 2001). Consistent
with its short half-life in the periphery, the data presented
herein unmistakably demonstrate that Aβ is also cleared from
the brain at a fast rate and in a time-dependent manner. About
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FIGURE 5 | Cellular localization of monomeric and oligomeric Aβ after intracerebral injection. Immunofluorescence microscopy analysis of serial frozen
sections from brains of mice injected with monomeric (A) and oligomeric (B) Aβ illustrates the co-localization of Aβ (red signal) with cell specific markers of neurons
(neurotubulin), endothelial cells (factor VIII), astrocytes (GFAP), choroid plexus epithelium (E-cadherin), and activated microglia (Iba-1), all in green fluorescence.
Co-localization is highlighted by the yellow fluorescence in the merged images. Magnification: bar represents 10µm in the neurotubulin stainings, 20µm for the GFAP
stainings, and 30µm in the case of the FVIII, E-cadherin and Iba-1 stainings.
25% of the monomeric peptide is cleared from the brain only
5 min after the intra-cerebral injection whereas the amount
of Aβ eliminated increases steadily with time reaching levels
of >60% at 60 min, the longest time-point evaluated in these
studies. Notably, transport across the brain-CSF barrier plays
a significant part in Aβ elimination as ∼3% of intra-cerebrally
injected 125I-Aβ was found in CSF after 5 min, and 13% 1 h
post-injection, consistent with previous reports—also employing
fresh monomeric preparations of radiolabeled Aβ1-40—which
estimated Aβ clearance to the CSF in 10–15% (Shibata et al., 2000;
Deane et al., 2003).
An impressive amount of research supports a pathogenic role
for Aβ oligomerization in AD. Small intermediate soluble Aβ
oligomers, similar to those employed in the current studies and
primarily consisting of SDS-resistant dimers and trimers (Haass
and Selkoe, 2007), have been implicated in synaptic dysfunction
and neuronal loss leading to the progressive dementia associated
in later stages of the disease with extensive Aβ pathology (Haass
and Selkoe, 2007; Walsh and Selkoe, 2007; Li et al., 2009; Jin
et al., 2011; Shankar et al., 2011). It is currently hypothesized
that accumulation of these Aβ oligomeric assemblies during
the disease progression translates in increasingly severe and
permanent changes in synaptic function. The 125I-Aβ1-40
clearance studies, showing higher brain retention and an ∼ 3 -
times lower eﬄux to the CSF for oligomeric Aβ in comparison
to the values observed for the monomeric form, add another
layer of pathogenic significance to these assemblies. Through a
delayed brain removal, oligomeric species—once formed—have
higher capability to exert their pathogenic activity. Furthermore,
since the process of multimerization is concentration dependent,
the persistence of oligomeric forms of Aβ within the brain
is likely to exacerbate the assembly of higher molecular mass
species and/or recruit soluble forms of Aβ into multimolecular
species in a nucleation/seeding effect which is increasingly
recognized as a significant contributor to the pathogenesis
of neurodegenerative disorders (Kane et al., 2000; Meyer-
Luehmann et al., 2006).
Targeted mass spectrometric analysis of the CSF collected at
different time points after the post-intracerebral Aβ injections
consistently demonstrated that Aβ is cleared to the CSF
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not only as a full-length peptide but also in the form
of numerous C-terminally truncated fragments, indicative of
catabolic cleavage by Aβ-degrading brain resident enzymes. This
enzymatic degradation takes place very fast, as evidenced by the
presence of the Aβ degradation products after only 5 min post-
injection. Comparative analysis of the Aβ catabolic footprints
with the time of CSF collection elapsed after the intracerebral
injection provides a clear indication of the preferential early
removal of these C-terminally degraded fragments in comparison
to the full-length Aβ1-40 providing support for an important
role of enzymatic degradation in the fast and efficient brain
Aβ clearance. Along this line, the higher retention exhibited by
Aβ oligomeric species may well relate not only to a decreased
efficiency in the eﬄux of these species per-se but also to a
lower susceptibility of these assemblies of being cleaved by brain
resident enzymes, as evidenced in the current studies by the lower
ratio of cleaved Aβ forms present in the CSF samples of animals
intracerebrally injected with Aβ1-40 oligomers. Indeed, the lower
susceptibility of Aβ aggregated species to enzymatic cleavage has
been previously documented—mostly in in vitro paradigms—
not only for Aβ, but also for other amyloid molecules associated
with different cerebral amyloidoses like the chromosome XIII
dementias, as well as for systemic forms of the disease (Haass and
Selkoe, 2007; Rostagno et al., 2007; De Strooper, 2010).
Enzyme-mediated clearance has received considerable
attention during the last decade, and many of the multiple
enzymes constituting the proteolytic machinery of the brain
have shown potential to participate in Aβ catabolism, among
them neprylisin, insulin degrading- and endothelin converting-
enzymes, plasmin as well as matrix metalloproteases (Selkoe,
2001; Morelli et al., 2002; Wang et al., 2006; Miners et al.,
2008; Saido and Leissring, 2012; Hernandez-Guillamon et al.,
2015). Reduced levels and/or decreased catalytic activity of these
Aβ-degrading enzymes as a result of age, genetic factors, and
specific disease conditions have been proposed to affect Aβ
accumulation, an issue well-documented in murine models in
which gene deletion of different proteases translate into increased
levels of Aβ deposition (Selkoe, 2001; Vardy et al., 2005; Wang
et al., 2006). Evidence of a genetic association of these proteases
with AD has only been reported for a few enzymes albeit no
consensus exists to the moment with regard to the importance
or reproducibility of these associations in the general AD
population (De Strooper, 2010). Nevertheless, in spite of this
elusive information, the relevance of these enzymatic processes
for brain clearance is supported in part by the current studies
which demonstrate the preferential elimination of truncated
C-terminal species to the CSF as well as by previous reports
highlighting the higher solubility and non-toxic characteristics
of the resulting truncated species (Hernandez-Guillamon et al.,
2015), features that point out to a beneficial role of Aβ enzymatic
processing for AD pathogenesis. The heterogeneous CSF Aβ
profile generated by enzymatic catabolism of injected Aβ1-40
correlates well with the heterogeneity of Aβ species present
in brain tissue and CSF biological samples. As illustrated in
Figure 6 for human CSF in normal individuals, Aβ heterogeneity
extends far beyond the classic Aβ1-40/Aβ1-42 dichotomy and
encompasses numerous Aβ truncated forms, primarily cleaved at
the C-terminus in CSF, and both at the C- and N-terminal ends
in brain specimens (Portelius et al., 2006; Tomidokoro et al.,
2010).
Immunofluorescence confocal studies performed following
intrahippocampal Aβ inoculation demonstrated localization of
the peptide with neurons, at microvessels in association with
endothelial and astrocytic components, as well as at the chroid
plexus epithelium. This peptide localization, which was also
visualized in the case of the inoculation of Aβ oligomers,
highlights different routes of cellular uptake, and clearance.
Internalization of Aβ by neurons can be clearly observed in
the experiments described herein, highlighting an important
route of cellular uptake, consistent with recent reports describing
the capability of neurons to uptake Aβ from interstitial fluid
(Kanekiyo et al., 2013). Indeed, although cellular uptake by
astrocytes, microglia, and vascular smoothmuscle cells have been
shown to participate in Aβ elimination (Wyss-Coray et al., 2001,
2003; Koistinaho et al., 2004; Kanekiyo et al., 2012) neuronal
uptake has received much less attention in spite of the high
vulnerability of these cells to Aβ-mediated toxicity. Recent data
indicate that neuronal LRP-1—a known endocytic receptor for
multiple ligands, including Aβ (Kanekiyo et al., 2013) and
predominantly expressed in the postsynaptic region and the cell
body (Bu et al., 1994; May et al., 2004)—mediates neuronal
Aβ uptake and subsequent degradation primarily by lysosome-
dependent pathways (Kanekiyo et al., 2013).
Immunofluorescence studies post-injection also
demonstrated the presence of Aβ in the cerebral
microvasculature, as indicated by colocalization of the peptide
with endothelial cells highlighted by their reactivity with
Factor VIII, suggestive of Aβ clearance across the BBB, a
well-studied pathway for the removal of Aβ monomers (Shibata
et al., 2000; Deane et al., 2009). The BBB, responsible for the
overall brain and CNS maintenance, is a highly specialized
structure which maintains neuronal homeostasis by regulating
the flux of electrolytes, metabolites, toxic molecules, and
circulating immune cells between the blood stream and the
brain parenchyma (Abbott et al., 2010; Di Marco et al., 2015).
It is primarily formed by basement membranes and capillary
endothelial cells which adhere to one another through tight
and adherens junctions, albeit astrocytes, and pericytes—
topographically located in close contact with the endothelium
(Allt and Lawrenson, 2001; Armulik et al., 2005)—are essential
contributors to the BBB phenotype. Through this permeability
barrier, the brain efficiently protects itself from harmful
compounds and precisely regulates its microenvironment
(Cecchelli et al., 2007). Small lipid-soluble molecules, such as
oxygen and carbon-dioxide can diffuse freely across the BBB,
whereas the exchange of larger molecules occurs by either active
transport through the cell body (transcytosis) or by paracellular
transport (Zlokovic, 2011; Lyros et al., 2014; Di Marco et al.,
2015). As macromolecules, Aβ peptides cross the BBB by active
transport. The influx from the blood to the brain is mediated
by the luminal residing receptor for advanced glycation end-
products (RAGE; Deane et al., 2003) whereas when complexed
to its carrier protein clusterin (apolipoprotein J) within the high
density lipoproteins, Aβ is transported into the brain through
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FIGURE 6 | The Aβ-peptidome in normal human CSF. The spectrum highlights the C-terminal heterogeneity of the Aβ species present in the CSF, extending far
beyond the classic Aβ1-42/Aβ1-40 dichotomy and reflecting the proteolytic action of local resident enzymes.
the clusterin receptor megalin (gp330 or LRP-2; Zlokovic et al.,
1996). LRP-1, predominantly localized on the abluminal side
of the cerebral endothelium (Shibata et al., 2000) as well as P-
glycoprotein (P-gp)—an ATP-dependent eﬄux pump with broad
specificity also abundant in the brain capillary endothelium—are
the main receptors responsible for Aβ eﬄux from brain-to-blood
(Shibata et al., 2000; Deane et al., 2003; Candela et al., 2010;
Di Marco et al., 2015). More recently, a novel protein in brain
endothelial monolayers has also been shown to play a role in
the brain clearance of Aβ. This protein, known as PICALM
(phosphatidylinositol binding clathrin assembly protein), is
abundantly expressed in brain capillary endothelium (Baig et al.,
2010; Parikh et al., 2014), and has been linked to AD in recent
genome wide association studies (Harold et al., 2009; Tanzi, 2012;
Lambert et al., 2013). Through the PICALM/clathrin-dependent
internalization of Aβ bound to LRP-1, this newly reported
pathway also contributes to Aβ endothelial transcytosis and
brain clearance.
Endothelial cells lining the cerebral microvasculature are
the primary cellular element forming the BBB albeit pericytes
and astrocytes are essential contributors to the physiological
function of this barrier (Zlokovic et al., 1996; Deane et al.,
2008). In particular astrocytes, which are in close anatomical
proximity to the brain microvasculature as their endfeet form
a lacework surrounding the outer surface of the endothelium
(Abbott, 2002), are crucial for the development of the specialized
BBB phenotype. This cross-talk with the brain endothelium
is now known to involve complex cell–cell exchange of
chemical signals responsible for the induction of the specific
features and the modulation of the cellular physiology of the
BBB. The immunohistochemical approach in the current work
demonstrates colocalization of Aβ with astrocytes surrounding
the microvasculature, as indicated by the overlapping staining
pattern of Aβ and the astrocytic marker GFAP suggestive of
a participation of these cells in Aβ clearance at the BBB.
Indeed, astrocytes have been shown as capable of binding and
internalizing Aβ in in vitro systems using live-cell imaging
methodologies although the precise mechanisms involved—
notably significantly less efficient for the clearing of Aβ fibrillar
assemblies—remain to be elucidated (Nielsen et al., 2010).
Analysis of the choroid plexus epithelium by
immunofluorescence studies indicates the presence of the
intracerebrally injected Aβ at this barrier structure. Notably, Aβ
reactivity was also associated with activated microglia within
the choroid plexus as highlighted by the overlapping signals of
Aβ with the Iba-1 microglial marker in association with this
epithelial barrier. The participation of microglia, the brain’s tissue
macrophages and the primary immune effectors within the CNS,
in the clearance of Aβ has been previously reported (Mandrekar
et al., 2009; Nielsen et al., 2010). These highly dynamic cells,
responsible for normal tissue maintenance, continually police
the brain extracellular environment taking up soluble nutrients
(Nimmerjahn et al., 2005). Microglia uptake Aβ peptides
through macropynocytic mechanisms, rapidly trafficking the
peptides into late endolysosomal compartments for subsequent
degradation, actively participating in the maintenance of Aβ
homeostasis (Mandrekar et al., 2009). The present data provide
support for the relevance of microglia-mediated uptake at the
level of the choroid plexus structures. The bulk flow of ISF
into the CSF through these specialized epithelium—which
notably shares many of the receptors involved in BBB clearance,
including LRP-1 and P-gp (Dietrich et al., 2008; Behl et al.,
2009)—has been reported to contribute 10–15% of brain
Aβ clearance, in agreement with the current report using
radiolabeled Aβ1-40 and supported by the localization of Aβ to
the epithelial choroid barrier.
Notably, the role of CSF in clearing Aβ along with waste and
toxic elements from the brain have become increasingly more
complex in the last few years with new evidence highlighting
the relevance of peri- and para-vascular intracerebral transport
routes (Bakker et al., 2016), the description of the glymphatic
system (Iliff et al., 2012), and the discovery of meningeal
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lymphatic vessels (Aspelund et al., 2015; Louveau et al., 2015),
the latter a potential clearance route yet to be studied. The ISF
bulk-flow clearance removes ISF—which contains Aβ as well as
other solutes and waste products—from the interstitium into
the CSF and perivascular space aided by the force resulting
from vessel pulsations. Evidence of drainage of ISF along
perivascular pathways, driving proteins, and fluid along blood
vessel walls were demonstrated early on through studies focusing
on the elimination of tracers injected into the brain parenchyma
(Bakker et al., 2016). These tracers diffuse through extracellular
spaces of the brain along basement membranes of capillaries
to drain out of the brain along basement membranes in the
tunica media of arteries and into the cervical lymph nodes
(Weller et al., 2008). Adding to the complexity of ISF/CSF
intracerebral circulation, a recycle of CSF through the brain ISF
has recently been described (Iliff et al., 2012). This pathway,
known as glymphatic transport system, is dependent on the
expression of the water channel protein aquaporin 4 by astrocytes
and on efficient arterial pulsations. Intra-cisternally injected
Aβ has been shown to be transported along this route, a
mechanism significantly reduced in aquaporin 4 knock-out mice.
Although the relative contributions of each of these systems to
overall clearance remains to be elucidated, these mechanisms
synergistically contribute to the elimination of extracellular Aβ
from the brain and alterations in any of these closely interlinked
mechanisms are likely to contribute to Aβ accumulation. The
intricate circulation of CSF is likely to influence the clearance
of other pathogenic protein in AD, the intracellular neuronal
protein Tau, which although not the focus of the current studies
has demonstrated relevance for the disease pathogenesis. Indeed,
Tau clearance is significantly less well-studied than Aβ clearance,
but it also seems to be less complex. Transporters specifically
mediating the passage of Tau through the BBB have not been
identified, which seem to suggest that the protein does not
undergo clearance through the BBB under normal physiological
conditions. Instead, tau is thought to be cleared from the brain
primarily by degradation, by ISF bulk flow into the CSF, and by
CSF absorption (Chesser et al., 2013; Iliff et al., 2014; Ueno et al.,
2016). As it is the case of Aβ and brain metabolic/waste products,
CSF absorption into the blood at the arachnoid villi as well its
reentry into the ISF by paravascular mechanisms and aquaporin
mediated circulation within the glymphatic system seem to
contribute to Tau clearance (Iliff et al., 2014; Ueno et al., 2016).
It is interesting to mention that most—if not all—of the
physiological mechanisms currently thought to participate in
brain clearance are severely affected by aging, feature that
may correlate with the age-associated characteristics of AD. In
this sense, the stiffening of cerebral arteries with age, lead to
reduced amplitude of pulsations and to a decreased efficacy in
perivascular and ISF drainage pathways, deficiencies accentuated
when vessels are compromised by amyloid deposits in cerebral
amyloid angiopathy which further impede the drainage of soluble
Aβ (Weller et al., 2008; Hawkes et al., 2011). A significant
decrease in CSF production and sluggish flow is also observed
in aging. This dwindling CSF dynamics, which greatly harms the
interstitial environment of neurons, is aggravated in AD in which
the expanding CSF space reduces CSF turnover rate further
compromising the sink action to clear harmful metabolites,
among themAβ (Johanson et al., 2008; Zeng et al., 2012), an effect
also impacted by the age-associated decreased functionality of
the choroid plexus-CSF system (Lustbader et al., 2004; Kheterpal
et al., 2006; Behl et al., 2009), as well as by the age-related
decrease in the levels of the Aβ eﬄux transporters both at the
choroid plexus and the BBB. All these changes individually or
concurrently have undisputed relevance for brain clearance and
a complete understanding of these mechanisms may provide new
insights leading to the delay or even the prevention of the onset
of AD.
Overall, the data presented herein, through intracerebral
injection of well-defined monomeric and low molecular mass
oligomeric Aβ assemblies in CB57BL6 mice, highlight the fast
physiologic brain elimination of the peptide providing a clear
indication of the detrimental role of oligomerization for brain
Aβ eﬄux. The findings clearly demonstrate that physiologic
clearance of brain interstitial Aβ follows local and systemic paths
and that in addition to the blood-brain barrier, local enzymatic
degradation, and the bulk flow transport through the choroid
plexus into the CSF play a crucial role. The complexity of
the interlinked Aβ brain removal mechanisms, encompassing
different cell populations and in some cases overlapping cellular
pathways explain to a certain point the lack of success of
therapeutic strategies targeting individual components of this
multiplex cascade. Our studies highlighting the diverse factors
influencing brain clearance and the various routes of elimination
open up new research opportunities for the understanding
of altered mechanisms triggering AD pathology and for the
potential design of combined therapeutic strategies.
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